MX2020006283A - Proceso para la preparación de opicapona y sus intermediarios. - Google Patents
Proceso para la preparación de opicapona y sus intermediarios.Info
- Publication number
- MX2020006283A MX2020006283A MX2020006283A MX2020006283A MX2020006283A MX 2020006283 A MX2020006283 A MX 2020006283A MX 2020006283 A MX2020006283 A MX 2020006283A MX 2020006283 A MX2020006283 A MX 2020006283A MX 2020006283 A MX2020006283 A MX 2020006283A
- Authority
- MX
- Mexico
- Prior art keywords
- opicapone
- preparation
- intermediates
- relates
- present
- Prior art date
Links
- HVGGGVAREUUJQV-CHHVJCJISA-N (4z)-4-[3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-1-ium-3-yl)-2h-1,2,4-oxadiazol-5-ylidene]-2-hydroxy-6-nitrocyclohexa-2,5-dien-1-one Chemical compound CC1=C(Cl)C(C)=[N+]([O-])C(Cl)=C1C(NO1)=N\C1=C\1C=C([N+]([O-])=O)C(=O)C(O)=C/1 HVGGGVAREUUJQV-CHHVJCJISA-N 0.000 title abstract 2
- 239000000543 intermediate Substances 0.000 title abstract 2
- 229950001673 opicapone Drugs 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención se refiere a un proceso para la preparación de opicapona y a un proceso para preparar intermediarios usados en el mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201721045330 | 2017-12-18 | ||
| PCT/IB2018/059598 WO2019123066A1 (en) | 2017-12-18 | 2018-12-04 | Process for the preparation of opicapone and intermediates thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020006283A true MX2020006283A (es) | 2020-12-09 |
Family
ID=66993196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020006283A MX2020006283A (es) | 2017-12-18 | 2018-12-04 | Proceso para la preparación de opicapona y sus intermediarios. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210087183A1 (es) |
| EP (1) | EP3728241A4 (es) |
| JP (1) | JP2021506762A (es) |
| KR (1) | KR20200100075A (es) |
| CN (1) | CN111511735A (es) |
| AU (1) | AU2018392845A1 (es) |
| BR (1) | BR112020011888A2 (es) |
| EA (1) | EA202091259A1 (es) |
| MX (1) | MX2020006283A (es) |
| PH (1) | PH12020550871A1 (es) |
| WO (1) | WO2019123066A1 (es) |
| ZA (1) | ZA202003590B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112375014A (zh) * | 2020-12-17 | 2021-02-19 | 重庆柳江医药科技有限公司 | 一种奥匹卡朋工艺杂质及制备方法和用途 |
| US20240300930A1 (en) * | 2021-02-26 | 2024-09-12 | Msn Laboratories Private Limited, R&D Center | Novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide |
| CN116986980A (zh) * | 2021-10-11 | 2023-11-03 | 常州锐博生物科技有限公司 | 一种香草酸的制备方法 |
| CN114015332A (zh) * | 2021-11-26 | 2022-02-08 | 广州双隆文化发展有限公司 | 一种马口铁印刷工艺 |
| GB202204798D0 (en) * | 2022-04-01 | 2022-05-18 | Bial Portela & Ca Sa | Prodrugs of opicapone |
| WO2024260874A1 (en) * | 2023-06-19 | 2024-12-26 | Medichem, S.A. | Process for preparing opicapone |
| CN120081837A (zh) * | 2025-02-14 | 2025-06-03 | 江苏天士力帝益药业有限公司 | 一种低单杂高纯度的奥匹卡朋中间体05的制备方法 |
| CN120490355B (zh) * | 2025-07-14 | 2025-09-23 | 重庆锐恩医药有限公司 | 同时检测奥匹卡朋起始物料中三种有关物质的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR058439A1 (es) * | 2005-07-26 | 2008-02-06 | Portela & Ca Sa | Derivados de nitrocatecol como inhibidores de comt. procesos de obtencion y composiciones farmaceuticas. |
| RU2550133C2 (ru) * | 2009-04-01 | 2015-05-10 | БИАЛ-ПОРТЕЛА энд КА., С.А. | Фармацевтические составы, включающие производные нитрокатехола, и способы их получения |
| WO2013089573A1 (en) * | 2011-12-13 | 2013-06-20 | BIAL - PORTELA & Cª., S.A. | Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor |
-
2018
- 2018-12-04 KR KR1020207017502A patent/KR20200100075A/ko not_active Withdrawn
- 2018-12-04 BR BR112020011888-5A patent/BR112020011888A2/pt not_active Application Discontinuation
- 2018-12-04 CN CN201880082145.7A patent/CN111511735A/zh not_active Withdrawn
- 2018-12-04 WO PCT/IB2018/059598 patent/WO2019123066A1/en not_active Ceased
- 2018-12-04 MX MX2020006283A patent/MX2020006283A/es unknown
- 2018-12-04 EP EP18892354.4A patent/EP3728241A4/en not_active Withdrawn
- 2018-12-04 JP JP2020531598A patent/JP2021506762A/ja active Pending
- 2018-12-04 EA EA202091259A patent/EA202091259A1/ru unknown
- 2018-12-04 US US16/954,501 patent/US20210087183A1/en not_active Abandoned
- 2018-12-04 AU AU2018392845A patent/AU2018392845A1/en not_active Abandoned
-
2020
- 2020-06-11 PH PH12020550871A patent/PH12020550871A1/en unknown
- 2020-06-15 ZA ZA2020/03590A patent/ZA202003590B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018392845A1 (en) | 2020-06-18 |
| ZA202003590B (en) | 2022-01-26 |
| BR112020011888A2 (pt) | 2020-11-24 |
| EP3728241A1 (en) | 2020-10-28 |
| EP3728241A4 (en) | 2021-02-24 |
| PH12020550871A1 (en) | 2021-04-05 |
| CN111511735A (zh) | 2020-08-07 |
| KR20200100075A (ko) | 2020-08-25 |
| WO2019123066A1 (en) | 2019-06-27 |
| JP2021506762A (ja) | 2021-02-22 |
| EA202091259A1 (ru) | 2020-09-22 |
| US20210087183A1 (en) | 2021-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550871A1 (en) | Process for the preparation of opicapone and intermediates thereof | |
| PH12018500711A1 (en) | Anti-pd1 antibodies and methods of use | |
| ZA201902141B (en) | Acid-alpha glucosidase variants and uses thereof | |
| EP4335874A3 (en) | Anti-hla-g antibodies and use thereof | |
| PH12018500950B1 (en) | Subcutaneous formulations of anti-cd38 antibodies and their uses | |
| IN2014CH00247A (es) | ||
| ZA201902140B (en) | Acid-alpha glucosidase variants and uses thereof | |
| GEP20196974B (en) | A novel crystalline form of a benzimidazole derivative and a preparation method thereof | |
| AU2015287674B2 (en) | Topical antiviral compositions and methods of using the same | |
| TW201613893A (en) | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine | |
| PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| IN2013MU00848A (es) | ||
| MX2017015137A (es) | Composicion farmaceutica oral de dosis diaria de isotretinoin. | |
| IN2014CH00840A (es) | ||
| IN2015CH01182A (es) | ||
| SG10201908248PA (en) | Processes for preparing fluoroketolides | |
| MX2019010640A (es) | Formas cristalinas de acido obeticolico. | |
| GEP201706795B (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
| PH12016501326A1 (en) | (s)-3'-methyl-abscisic acid and esters thereof | |
| MX383313B (es) | Compuestos de quinolinilciclohexilpropanamida sustituidos y metodos mejorados para su preparacion | |
| PH12017500499A1 (en) | Synthesis of ent-progesterone and intermediates thereof | |
| PH12018501166B1 (en) | Concentrated gibberellin solution formulations | |
| NZ721832A (en) | Solid forms of tenofovir | |
| MX2017008776A (es) | Relleno para preparar un producto refractario, un procedimiento para preparar un producto refractario, un producto refractario, y uso de un producto refractario. | |
| MX382187B (es) | Extracto concentrado de sabadilla. |